fig2

Leelamine suppresses cMyc expression in prostate cancer cells <i>in vitro </i>and inhibits prostate carcinogenesis <i>in vivo</i>

Figure 2. Effect of cMyc overexpression on the anticancer effects of leelamine (LLM). upper: Western blots showing overexpression of the cMyc protein in stable cMyc overexpressing cells (cMyc) compared to empty vector (EV) transfected control cells. The numbers above bands represent quantitation of the cMyc protein level relative to corresponding EV cells. middle and bottom: Clonogenic assay using EV and cMyc cells following treatment with vehicle or LLM. The results shown are mean ± SD (n = 3). Significantly different (P < 0.05) compared with *ethanol-treated control, and #between EV and cMyc groups by one-way ANOVA followed by Bonferroni’s test (A). Trypan blue dye exclusion assay using EV and cMyc cells following treatment with vehicle or LLM. The results shown are mean ± SD (n = 3). Significantly different (P < 0.05) compared with *ethanol-treated control, and #between EV and cMyc groups by one-way ANOVA followed by Bonferroni’s test (B). Cell migration assay using EV and cMyc cells following treatment with vehicle or LLM. The results shown are mean ± SD (n = 3). Significantly different (P < 0.05) compared with *ethanol-treated control, and #between EV and cMyc groups by one-way ANOVA followed by Bonferroni’s test (C). Each experiment was performed twice, and the results were generally consistent.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/